AltruBio

Our Science

ADDRESSING UNMET MEDICAL NEEDS

Our clinical-stage program, ALTB-168, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.

R&D Update on AltruBio's Immune Checkpoint Enhancer Platform for Immunological Diseases

Therapeutic Platform

Regulation of T-cell homeostasis

ALTB-168 : Agonistic antibody with a unique mechanism of action—regulation of T cell homeostasis

Our lead inflammation drug candidate, ALTB-168, is an immune checkpoint agonist antibody targeting PSGL-1/CD162. It has demonstrated signs of clinical efficacy in psoriasis (phase II),psoriatic arthritis (phase II), ulcerative colitis (phase II) and steroid/treatment refractory-acute GvHD patients (phase I).

ALTB-168’s unique mechanism of action provides a natural regulation of T cell homeostasis that preferentially down-regulates late-stage chronically activated T cells without affecting resting T cells and early-activated T cells. Because pathogenic T cells underlying the inflammatory conditions are usually in late-stage, chronically activated state, eliminating this population of cells can potentially result in controlling autoimmune inflammation associated with T cell, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes and GvHD. Treatment with ALTB-168 could result in durable and long-term responses as the therapy is designed to target the pathogenic T cells underlying these inflammatory conditions rather than the inflammatory cytokines they produce. In addition, since resting T cells are not affected, normal immune defenses are not impacted.

ALTB-168 : Clinical-Stage Platform in Immunology

ALTB-168 has demonstrated signs of clinical efficacy in Psoriasis (phase II), Psoriatic Arthritis (phase II), Ulcerative Colitis (phase II) and steroid/treatment refractory-acute GvHD patients (phase I).

Our Products

INNOVATIVE SOLUTIONS

AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.

Apr, 2024

ALTB-168: ALTB-168 is a humanized therapeutic antibody with a unique mechanism of action, preferentially inducing down regulation of late-stage, chronically activated T cells. This novel antibody effectively targets chronic pathogenic T cells while fully maintaining host defense, leading to durable clinical efficacy without increasing the risk of infection or cancer. These two characteristics, which have been well demonstrated in our proof of concept clinical studies, offer a sustainable competitive advantage over existing therapies.

ALTB-168 has demonstrated signs of clinical efficacy in Phase II clinical trials for T-cell mediated diseases such as psoriasis, psoriatic arthritis and ulcerative colitis. This innovative drug candidate has the potential to bring game-changing benefits to patients with many other T-cell mediated diseases. We have also completed a phase I study in patients who develop steroid/treatment-refractory acute graft versus host disease (SR/TR-GVHD) after allogeneic hematopoietic cell transplantation (HCT), as well as an ongoing clinical study in the front-line setting of acute GVHD.

ALTB-268: Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a tetravalence molecule to achieve better efficacy. From preclinical and phase 1 clinical study ALTB-268 exhibits not only comparable safety profiles, but also improved potency in down-regulating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equivalent efficacy in clinical is expected.

Publications